Midecamycin
|
WikiDoc Resources for Midecamycin |
|
Articles |
|---|
|
Most recent articles on Midecamycin Most cited articles on Midecamycin |
|
Media |
|
Powerpoint slides on Midecamycin |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Midecamycin at Clinical Trials.gov Clinical Trials on Midecamycin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Midecamycin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Midecamycin Discussion groups on Midecamycin Patient Handouts on Midecamycin Directions to Hospitals Treating Midecamycin Risk calculators and risk factors for Midecamycin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Midecamycin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Midecamycin is a macrolide antibiotic. Synthesized from Streptomyces mycarofaciens.
Physical Properties
Melting point vary depending on the compound type. It may also vary depending on the source consulted. Example:
For the A1 type:
The Merck Index reports 155-156 Celsius. The Japanese Pharmacopoeia reports 153–158 Celsius.
For the A3 type:
The Merck Index reports 122-125 Celsius.
References
